Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT05841472 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Squamous Non Small Cell Lung Cancer

Interventions

DRUG: Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin

Sponsor

CrystalGenomics, Inc.